Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma
Editor Note: For more information about this release, please scroll to bottom.
LONDON, October 20, 2014
Phase II Data in Crohn's Disease for Celgene's Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014
SELLAS Life Sciences Group Selects PPD As Its Strategic CRO Partner To Advance Zolpidem And WT1 Cancer Vaccine
NewLink Genetics Announces Exclusive Worldwide Licensing Agreement for Development of NLG919, an IDO Inhibitor in Phase 1, and Research Collaboration for the Discovery of Next Generation IDO/TDO Inhibitors
THOUSAND OAKS, Calif., Oct.